The efficacy and safety of moxibustion for chemotherapy-induced gastrointestinal adverse reaction
| Autor: | Yi-Feng Bai, Xiao-Qin Dai, Yi Zhou, Han-Xiao Zhang, Peng Lv, Chuan-Yi Zuo, Rui-Zhen Huang, Cheng-Shun Zhang, Qian-Ning Mo |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
business.industry medicine.medical_treatment MEDLINE General Medicine Moxibustion Cochrane Library law.invention Clinical trial 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Quality of life law 030220 oncology & carcinogenesis Meta-analysis medicine 030212 general & internal medicine Intensive care medicine Adverse effect business |
| Zdroj: | Medicine. 99:e22042 |
| ISSN: | 1536-5964 0025-7974 4202-0182 |
| DOI: | 10.1097/md.0000000000022042 |
| Popis: | Background Many cancer patients experience gastrointestinal adverse reaction during chemotherapy. Pharmacological interventions are commonly used to treat chemotherapy-induced gastrointestinal side effects but have various limitations. Clinical trials have indicated that moxibustion may alleviate gastrointestinal dysfunction and improve quality of life (QoL) after chemotherapy. This study aims to assess the efficacy and safety of moxibustion for chemotherapy-induced gastrointestinal adverse reaction through a systematic review and meta-analysis. Methods All randomized controlled trials (RCTs) related to moxibution targeting chemotherapy-induced gastrointestinal adverse reaction will be searched in online databases, such as PubMed, EMBASE, the Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), the Chinese Scientific Journal Database (VIP Database) and WanFang Database from their inception to May 1, 2020. The primary outcome is the incidence and severity of chemotherapy-related gastrointestinal toxicities (nausea and vomiting, diarrhea and constipation). The secondary outcomes include the quality of life, biological parameters' alteration, and adverse events. Study selection, data extraction, and assessment of risk of bias will be performed independently by 2 researchers. The Cochrane Collaboration's Review Manager (RevMan 5.3) software will be used to conduct the direct meta-analysis. Results This study will provide a comprehensive review of the available evidence for the treatment of chemotherapy-induced gastrointestinal adverse reaction with moxibustion. Conclusion The conclusion of this study will provide evidence to judge whether moxibustion is an effective and safety therapeutic intervention for chemotherapy-induced gastrointestinal adverse reaction. Prospero registration number CRD42020182990. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|